

Expertenbrief zum Thromboembolierisiko unter hormonaler Kontrazeption

Avis d'experts concernant le risque thromboembolique sous contraception hormonale

Literatur / Références

1. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. *Lancet*. Dec 16 1995;346(8990):1593-1596.
2. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. *Lancet*. Dec 16 1995;346(8990):1589-1593.
3. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. *N Engl J Med*. May 17 2001;344(20):1527-1535.
4. Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. *Thromb Haemost*. Jul 2000;84(1):15-21.
5. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. *Lancet*. Jan 11 1997;349(9045):83-88.
6. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. *BMJ*. 2011;343:d6423.
7. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. *BMJ*. 2011;342:d2139.
8. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. *CMAJ*. Dec 13 2011;183(18):E1319-1325.
9. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. *BMJ*. 2009;339:b2890.
10. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. *BMJ*. Jan 13 1996;312(7023):83-88.
11. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. *Arch Intern Med*. Mar 23 1998;158(6):585-593.
12. Ho WK, Hankey GJ, Eikelboom JW. The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. *Med J Aust*. Aug 4 2008;189(3):144-147.
13. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. *N Engl J Med*. Dec 20 2001;345(25):1787-1793.
14. The European Consensus Development Conference 2002: Sex Steroids and Cardiovascular Diseases. On the route to combined evidence from OC and HRT/ERT. *Maturitas*. Jan 30 2003;44(1):69-82.
15. Farley TM, Collins J, Schlesselman JJ. Hormonal contraception and risk of cardiovascular disease. An international perspective. *Contraception*. Mar 1998;57(3):211-230.
16. Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints. CHC-CVD final report 111022v2. 2011.
17. James AH. Pregnancy and thrombotic risk. *Crit Care Med*. Feb 2010;38(2 Suppl):S57-63.
18. Rosendaal FR. Venous thrombosis: a multicausal disease. *Lancet*. Apr 3 1999;353(9159):1167-1173.
19. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. *BMJ*. 2009;339:b2921.
20. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. *Contraception*. May 2007;75(5):344-354.
21. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. *Obstet Gynecol*. Sep 2007;110(3):587-593.

22. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. *BMJ*. 2011;342:d2151.
23. Lewis MA, Spitzer WO, Heinemann LA, MacRae KD, Bruppacher R. Lowered risk of dying of heart attack with third generation pill may offset risk of dying of thromboembolism. *BMJ*. Sep 13 1997;315(7109):679-680.
24. Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. *N Engl J Med*. Jun 14 2012;366(24):2257-2266.
25. Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. *Contraception*. Sep 1997;56(3):129-140.
26. Neue Studien zum Risiko von Venenthrombosen und Lungenembolien unter hormonalen Verhütungsmitteln – Empfehlungen Swissmedic 5.12.2011. 2011.
27. Elliott TC, Montoya CC, Williams R. Clinical inquiries: how does VTE risk for the patch and vaginal ring compare with oral contraceptives? *J Fam Pract*. Oct 2008;57(10):680, 683, 685.